Drug
Tafamidis clinical trials
Also written Fx-1006A and Vyndaqel.
- studies test it
- 30
- open now
- 0
- in phase 3
- 7
- first study started
- 2007
How studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
30 studies that test it; most in 2008 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 18
- Phase 2
- 4
- Phase 3
- 7
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 29 · Other 1
Pfizer (29) · University of Texas Southwestern Medical Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses tafamidis is read from its arms, and is right about nine times in ten.
Testing it · 30
- A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fasting ConditionsCompletedPhase 1PfizerNCT07587697Written as Tafamidis
- A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fed ConditionsTerminatedPhase 1PfizerNCT07470866Written as Tafamidis (Reference)
- Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart TransplantationActive, not recruitingPhase 4University of Texas Southwestern Medical CenterNCT05489523Written as Tafamidis 61 MG
- A Study to Compare Two Forms of Study Medicine Tafamidis in the Blood in Healthy AdultsCompletedPhase 1PfizerNCT06705569Written as Tafamidis 61 mg free acid tablet (Test)
- Long-term Safety of Tafamidis in Subjects With Transthyretin CardiomyopathyCompletedPhase 3PfizerNCT02791230Written as Tafamidis
- A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)CompletedPhase 4PfizerNCT04814186Written as Tafamidis
- A Study to Learn How Different Forms of Study Medicine Tafamidis Are Taken Up Into The Blood in Healthy AdultsCompletedPhase 1PfizerNCT06273839Written as Tafamidis 61 mg free acid tablet (Test 1)
- A Study Comparing Two Forms of Tafamidis Without Food and the Amount of Tafamidis in the Blood With FoodCompletedPhase 1PfizerNCT05498701Written as Tafamidis meglumine capsule (Reference)
- The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy PatientsCompletedPhase 4PfizerNCT04828993Written as tafamidis meglumine
- Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin AmyloidosisCompletedPhase 3PfizerNCT00925002Written as Tafamidis
- A Study to Determine the Bioequivalence of Two Doses of TafamidisCompletedPhase 1PfizerNCT04575116Written as Tafamidis meglumine capsule
- Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid CardiomyopathyCompletedPhase 3PfizerNCT00935012Written as tafamidis
- A Drug-Drug Interaction Study To Estimate The Effect Of Tafamidis On Rosuvastatin PharmacokineticsCompletedPhase 1PfizerNCT04253353Written as tafamidis
- Safety and Efficacy of Tafamidis in Patients With Transthyretin CardiomyopathyCompletedPhase 3PfizerNCT01994889Written as Tafamidis
- Phase I Safety, Pharmacokinetics and Bioavailability Study Comparing Rate and Extent of Absorption of Two Different Forms of Tafamidis (PF-6291826)CompletedPhase 1PfizerNCT03662191Written as Tafamidis
- A Study Comparing Amounts of 2 Different Forms of Tafamidis (PF-6291826) in the BloodCompletedPhase 1PfizerNCT03266705Written as tafamidis
- A Study Comparing the Amounts of 2 Different Forms of Tafamidis (PF06291826), Both With and Without Food, In the BloodCompletedPhase 1PfizerNCT03280173Written as tafamidis
- A Study Comparing Amounts of Tafamidis (PF-06291826) in the Blood Without Food in Healthy VolunteersCompletedPhase 1PfizerNCT02746926Written as tafamidis
- A Study Comparing Amounts of Tafamidis In The Blood Without FoodCompletedPhase 1PfizerNCT02697864Written as tafamidis
- A Study Comparing Amounts of Tafamidis In The Blood With Or Without FoodCompletedPhase 1PfizerNCT02534740Written as tafamidis
Codes
What other systems call tafamidis · ClinicalTrials.gg INT005569
- MeSH (NLM) C547076tafamidisConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 8FG9H9D31JTAFAMIDISConfirmed FDA, NLM, Wikidata
- RxNorm 1545063Confirmed FDA, Wikidata
- Wikidata Q519447tafamidisConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C84193TafamidisOne source FDA
- DrugBank DB11644One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C547076 | tafamidis | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 8FG9H9D31J | TAFAMIDIS | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1545063 | — | Confirmed FDA, Wikidata |
| Wikidata | Q519447 | tafamidis | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C84193 | Tafamidis | One source FDA |
| DrugBank | DB11644 | — | One source Wikidata |
Also registered as tafamidis meglumine (UNII ZU7CF08A1A · RxNorm 1727003).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.